Letter from the Editor


Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at

Product Description

The era of Pharma 3.0 is upon us. According to Ernst & Young (EY), several industry trends, including healthcare reform, health IT, comparative effectiveness, and the rising confidence in consumer power, are driving nontraditional companies into the life-sciences sector. These factors, among others, will continue to prompt pharmaceutical companies to broaden their focus from producing new medicines to delivering “healthy outcomes” — a shift that will encompass creative partnerships and business model innovation.
In its recent Progressions report, EY describes the transition of the industry’s long-standing, vertically integrated, blockbuster-driven model, defined as Pharma 1.0, to today’s Pharma 2.0 business model, to the upcoming…